This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Gentium Announces Presentation Of Defibrotide Data At The American Society Of Hematology

VILLA GUARDIA, Italy, Nov. 10, 2010 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that three abstracts on Defibrotide will be presented at the 52 nd Annual Meeting and Exposition of the American Society of Hematology to be held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

Poster session: Clinical Care – Transplantation Regimen Toxicities and Engraftment: Poster II, Hall A3/A4, Monday, December 6, 2010, 6:00 PM - 8:00 PM

"Meta-analysis of Defibrotide (DF) in the treatment of severe hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with comparison to a Historical Control (HC)" (Poster Board III-260). P. Richardson et. al., Dana-Farber Cancer Institute, Boston, MA, USA.

"Safety of Defibrotide (DF) in Stem Cell Transplant (SCT) patients (Pts)" (Poster Board III-261). S. Corbacioglu et al., University of Regensburg, Regensburg, Germany.

Oral session: Clinical Care – Transplantation Regimen Toxicities and Engraftment: Transplant Related Toxicities, Room 110A, Tuesday, December 7, 2010, 8:45 AM

"Defibrotide (DF) in the treatment of severe hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): results of a treatment IND expanded access protocol" (Abstract #906), P. Richardson et. al., Dana-Farber Cancer Institute, Boston, MA, USA.

For more details on the congress, please visit the official congress web site:

http://www.hematology.org/Meetings/Annual-Meeting/

About Gentium

Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. FDA and Orphan Medicinal Product Designation by the European Commission both to treat and to prevent VOD and Fast Track Designation by the U.S. FDA to treat VOD.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,224.61 +33.24 0.19%
S&P 500 1,996.87 -5.29 -0.26%
NASDAQ 4,615.2630 -22.7310 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs